Participants: Estimated enrollment is 66 patients. Type of cells used: Vaccine is based on the pDC cell line HLA-A*02:01 that is lethally irradiated and then pulsed with peptides from target tumor antigens. Primary objective: To assess the tolerability, the immunogenicity and the preliminary clinical activity of the therapeutic cancer vaccine, PDC*lung01, either alone or associated with anti-PD-1 treatment in patients with NSCLC. This evidence concerns the gene HLA-A and cancer.